CAGE Ionic Liquid Carrier for Toxic-Free Active Compound Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional solvents used for delivering active compounds are often toxic and irritant, limiting their effectiveness due to adverse side effects, especially in vivo applications.
Innovation Solution
The use of the ionic liquid Choline And Geranate (CAGE) as a carrier, which enhances the delivery of active compounds across membranes without causing toxic side effects, including oral, subcutaneous, and parenteral routes, and is effective in treating various conditions such as obesity and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional solvents are used to deliver active compounds, then the uptake of active compounds is improved, but toxic side effects and irritation occur
Solution Approach 1:
The patent changes the chemical parameters of the solvent system by using ionic liquids (specifically CAGE - choline and geranate) instead of conventional organic solvents. This parameter change maintains the ability to deliver active compounds while eliminating toxicity and irritation, as the ionic liquid is biocompatible and non-toxic.
Solution Approach 2:
The invention employs a composite approach by combining ionic liquid (CAGE) with active compounds to create a delivery formulation. This composite material leverages the unique properties of ionic liquids - both their ability to enhance compound uptake and their biocompatibility - to resolve the contradiction between delivery effectiveness and safety.
2Object-affected harmful factors
If ionic liquid CAGE is used as carrier, then toxic side effects are eliminated, but antimicrobial properties may cause issues
Solution Approach 1:
The patent converts the antimicrobial property of CAGE from a potential harm into a benefit by demonstrating that it selectively targets pathogenic bacteria while being safe for human tissues. The antimicrobial activity is harnessed to prevent infections at delivery sites without causing system-wide harm, turning a previously problematic property into a therapeutic advantage.
Solution Approach 2:
The invention applies local quality by concentrating the antimicrobial activity of CAGE at specific delivery sites (such as tumor locations or infection sites) rather than system-wide. This localized application allows the antimicrobial properties to protect at the point of delivery while avoiding harmful effects in other body systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CAGE improves the bioavailability and stability of active compounds, allowing for effective delivery and treatment of conditions like obesity and cancer without the toxicities associated with traditional solvents, while maintaining antimicrobial properties.
Implementation Method 1
enhances the delivery of active compounds across membranes
Implementation Method 2
improves the bioavailability and stability of active compounds
Data Source
AI summary
The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.